How the Alzheimer's disease (AD) peptide b-amyloid (Ab) disrupts neuronal function in the disease is unclear. Factor (F) XII initiates blood clotting via FXI, and thrombosis has been implicated in AD. Ab triggers FXII-dependent FXI and thrombin activation, evidence of which is seen in AD plasma. Ab-triggered clotting could contribute to neuronal dysfunction in AD and be a novel therapeutic target.
Introduction
Alzheimer's disease (AD) is a fatal cognitive disorder affecting~26 million people worldwide. There is evidence that the AD-related peptide b-amyloid (Ab) is a primary driver of both early-onset and late-onset disease [1, 2] . While the direct neuronal toxicity of Ab in vitro is well documented, the mechanism by which Ab disrupts neuronal function in AD patients is still unclear [1] .
It is unlikely that direct toxicity of Ab to neurons is the sole factor responsible for eliciting AD. Indeed, cerebrovascular pathology is present in the majority of AD patient brains upon autopsy [3, 4] , but whether it contributes to AD etiology or is simply a comorbidity is debated. A causative role for vascular pathology in AD is suggested by the increased risk of AD in vascular disease states such as atherosclerosis, diabetes, hypertension, and hypercholesterolemia [5] . In keeping with a link between AD and vascular dysfunction, accumulating evidence suggests that AD patients and mouse models exhibit a prothrombotic state: AD patients have numerous prothrombotic markers in the circulation [6] , AD mouse models have a propensity to form thrombi [7, 8] , and AD patients are at a higher risk for microinfarcts [9, 10] and stroke [11] . Furthermore, prothrombotic conditions such as elevated levels of D-dimer, prothrombin fragment 1 + 2, coated platelets, plasma homocysteine, and fibrinogen, as well as the presence of factor V Leiden, silent brain infarcts, microinfarcts, and stroke, all contribute to AD onset and progression [6, 10, [12] [13] [14] [15] . The idea that a prothrombotic state plays a role in AD is further supported by improvements in AD pathology and memory in patients [16, 17] and mouse models [18, 19] following treatment with anticoagulants.
Coagulation factor XII (FXII) is a circulating protein that, when converted to activated FXII (FXIIa), can initiate two pathways: the intrinsic coagulation pathway through activation of FXI, and the kallikrein-kinin system through activation of prekallikrein. Since Ab has been shown to interact with and activate FXII [20] [21] [22] [23] , and FXII has been implicated in thrombosis in mice [24] , one possibility is that Ab may contribute to the prothrombotic environment in AD through FXII-dependent activation of FXI. Although Ab has not been shown to trigger FXII-dependent FXI activation in vitro or in vivo, it has been implicated in FXII-dependent activation of the kallikrein-kinin system in vitro [20] [21] [22] and in mouse models [25] . Furthermore, increased activation of the kallikrein-kinin system is found in AD patient plasma [25] , brain [26] , and cerebrospinal fluid (CSF) [27] , suggesting a role for FXII-driven processes in AD pathology. In the circulation, FXII can encounter increased concentrations of Ab at sites of potential thrombosis, including the luminal side of cerebral capillary walls (where Ab enters the blood through the blood-brain barrier [BBB]) [28] , atherosclerotic lesions [29] , sites of platelet activation [30] , and areas of erythrocyte accumulation [31, 32] . A role for circulating Ab in AD is supported by increased levels of plasma Ab in populations at high risk for AD (Down syndrome patients, familial AD patients, and family members of AD patients) [33, 34] , and in sporadic AD patients prior to the onset of symptoms [33] [34] [35] . Moreover, elevated plasma Ab levels increase AD risk [36, 37] .
Here, we show that Ab oligomers promote coagulation by inducing FXII-mediated thrombin generation through the intrinsic coagulation pathway. We demonstrate the relevance of these findings to AD by showing decreased levels of FXI and its inhibitor C1 esterase inhibitor (C1inh), and increased levels of fibrin, in AD patient plasma, suggesting activation of FXI and the intrinsic coagulation pathway. The promotion of coagulation by Ab42 provides a possible new mechanism for the prothrombotic state observed in AD patients, and suggests new mechanisms by which it could contribute to neuronal dysfunction. Inhibition of the activation or activity of FXII in AD patients might therefore be an attractive novel therapeutic approach.
Materials and methods

Ab preparation
Ab42, Ab40 and Ab42 E22Q Dutch (Anaspec, Fremont, CA, USA) monomers and oligomers were prepared as in [38] . For fibrils, Ab42 was dissolved in 60 lL of 1% NH 4 OH, adjusted to 200 lM with 50 mM Tris (pH 7.4) and 150 mM NaCl, and incubated at 37°C, with shaking, for 7 days. Ab preparations were confirmed by transmission electron microscopy (TEM) at Rockefeller University's Electron Microscopy Resource Center.
Blood collection and plasma preparation
Experiments with human plasma were approved by Rockefeller's Institutional Review Board. Blood was drawn from healthy volunteers, who had given informed, written consent, with 21-gauge 0.75-inch butterfly needles with a multi-adapter for S-Monovette (Sarstedt, Newton, NC, USA) into S-Monovette tubes containing 1/10 volume 0.106 mM trisodium citrate solution at Rockefeller University Hospital and Karolinska Institute Hospital. To obtain platelet-rich plasma (PRP), blood was centrifuged at 130 9 g for 10 min, and the top half of the PRP was removed. To obtain platelet-poor plasma (PPP), blood was centrifuged twice at 2000 9 g for 10 min. PPP was frozen immediately at À 80°C. Microparticle-free plasma was prepared by ultracentrifugation at 100 000 9 g for 30 min at 4°C.
Mouse lines
Animal care and experimental procedures complied with the principles of laboratory and animal care established by the National Society for Medical Research, and were approved by the Stockholm Norra Djurf€ ors€ oksetiska N€ amnd. FXII À/À [39] and FXI À/À [40] mice backcrossed to C57BL/6 mice for > 10 generations and age-matched C57BL/6 control mice (Charles River, Wilmington, MA, USA) were used. Blood was collected with repel-gel (Sigma, St. Louis, MO, USA) coated glass capillary tubes into citrated Eppendorf tubes. PPP was prepared by centrifugation at 1500 9 g for 15 min.
Thrombin generation in plasma
Thrombin generation in normal or FXII-deficient human plasma (George King Biomedical, Overland Park, KS, USA) was measured by calibrated automated thrombogram (CAT), as described in [41] . In some cases, plasma was preincubated for 30 min with an antibody against FXIIa [42] , FXI À/À and C57BL/6 mouse plasma was measured as described above, with modifications as in [43] . 
FXI, C1inh and fibrin levels in human plasma
Plasma from AD patients and non-demented (ND) controls was obtained from the University of Kentucky Sanders-Brown Center on Aging (group 1) and Washington University Knight Alzheimer's Disease Research Center (group 2). Group 1 AD cases were defined by clinical diagnosis of AD and by a postmortem Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuritic plaque score [44] of B or C, corresponding to probable or definite AD, respectively. ND cases had a CERAD score of 0 and no clinical diagnosis of AD (Table S1 ). Group 2 AD cases had a Clinical Dementia Rating (CDR) score (measuring cognitive function) [45] of ≥ 0.5 and CSF Ab42 levels of < 500 pg mL À1 , and ND cases had a CDR score of 0 and CSF Ab42 levels of > 500 pg mL À1 (Table S2) . For group 1, blood was drawn into heparinized plastic Vacutainer tubes. For group 2, blood was drawn with EDTA-coated syringes into polypropylene tubes containing a final concentration of 5 mM EDTA. Equal amounts of total protein from each sample (as determined with the bicinchoninic acid assay) were analyzed by western blotting with antibodies against FXI (Haematologic Technologies), C1inh (Proteintech, Chicago, IL, USA), fibrin b-chain (59D8 [46] ), D-dimer (AbD Serotec, Raleigh, NC, USA), and transferrin (Abcam, Cambridge, MA, USA). Purified FXI, C1inh (Athens Research and Technology, Athens, GA, USA) and FXI-deficient plasma (George King Biomedical) served as controls.
Statistical analysis
Data are presented as vertical scatter plots with medians, and are reported as medians with 25th and 75th percentile ranges (median [25th-75th percentile range]), or presented as bar graphs (mean AE standard deviation). Comparisons between groups were performed with the unpaired, two-tailed Mann-Whitney test or one-way ANOVA followed by Tukey's multiple comparison test. Correlations were analyzed by the use of Spearman's correlation coefficient (r). P-values of ≤ 0.05 were considered to be significant. Statistical analyses were performed with GRAPHPAD PRISM 5 (GraphPad Software, La Jolla, CA, USA).
Results
Ab42 promotes thrombin generation in plasma
To determine whether Ab42 is prothrombotic, we quantified thrombin generation in human plasma by CAT [41] in the presence of oligomeric Ab42, a toxic assembly that correlates with disease severity [47] . The oligomeric composition of Ab42, which is stable for 24 h at room temperature and 37°C (Fig. S1 ), was confirmed by electron microscopy (Fig. 1A) . In the absence of exogenous activators, a small thrombin burst was detectable after a long lag period (vehicle; Fig. 1B ). Addition of Ab42 to PRP promoted thrombin generation in a dose-dependent manner, as indicated by a shortening of the lag time to the thrombin burst and an increase in peak height (maximum thrombin formed) (Fig. 1B) . A similar prothrombotic effect was observed in PPP ( Fig. 1C) , indicating that platelets are not required for the effect. However, Ab42 had no effect in microparticle-free plasma (Fig. 1D ). Supplementing microparticle-free plasma with phospholipids restored Ab42's ability to trigger thrombin generation (Fig. 1D) , indicating that the presence of phospholipid surfaces (found on platelets and microparticles) is required for Ab42-mediated thrombin generation. The prothrombotic effect is specific to Ab42, since amylin, another amyloid-forming peptide, failed to induce thrombin generation (Fig. 1E ).
Ab42-mediated thrombin generation is FXII-dependent
Thrombin is generated through activation of the intrinsic (FXII-driven) or extrinsic (tissue factor [TF]-driven) coagulation pathways. To determine which pathway is activated by Ab42, CAT experiments were performed in the presence of a FXIIa function-blocking antibody [42] (to block the intrinsic pathway), or with active site-inhibited FVII (ASIS; to block the extrinsic pathway). The FXIIa antibody abolished Ab42-induced thrombin generation ( Fig. 2A) , whereas ASIS had no inhibitory effect (Fig. 2B) , indicating that Ab42 is prothrombotic via the FXIIa-driven intrinsic coagulation pathway. The FXIIa antibody specifically blocks FXIIa-mediated thrombin generation, since it abolished thrombin generation initiated by kaolin (an FXII activator) but did not interfere with TF-initiated thrombin generation. As expected, ASIS inhibited TF-initiated thrombin generation (Fig. S2) .
To further examine the role of FXII in Ab42-mediated thrombin generation, we analyzed the effect of Ab42 in FXII-deficient human plasma (with no detectable plasma FXII antigen; Fig. 2C inset) . Ab42 failed to trigger thrombin generation in FXII-deficient plasma (Fig. 2C,  dashed curves) . To examine the role of Ab42 in a system in which FXII is completely absent, we tested plasma from mice that do not express any FXII (FXII À/À ). Whereas Ab42 promoted thrombin generation in wildtype (WT) mouse plasma, no effect was seen in FXII À/À mouse plasma (Fig. 2D) .
Since FXII-deficient or FXII-neutralized plasmas have normal levels of downstream coagulation factors, the results also indicate that thrombin generation is not driven through direct activation of these factors by Ab42. However, Ab42 may potentiate downstream factors when they are in the activated state, which may be produced by low-level, well surface-mediated FXII activation (e.g. the background thrombin signal in Fig. 1B) . To address this possibility, thrombin generation in FXII-deficient human plasma was measured following activation with FXIa, which activates downstream members of the coagulation cascade. Ab42 had no effect on thrombin generation in plasma activated with low levels of FXIa (Fig. 2C, solid  curves) , indicating that it does not enhance the activity of FXIa or any downstream factors. Furthermore, Ab42 had no effect on thrombin generation in plasma from mice that have normal levels of FXII but do not express FXI (Fig. S3) , confirming that the pathway enhanced by Ab42 involves FXIIa-mediated activation of FXI and not FXIIa-mediated activation of another substrate. (Fig. 2B) . All experiments were performed in duplicate, and averaged curves are presented. Ab, b-amyloid.
Ab triggers FXII-dependent FXI activation in vitro
FXII undergoes autoactivation on negatively charged surfaces. Since autoactivation of FXII has only been shown with fibrillar Ab40 and in the presence of ZnCl 2 [20] , we first determined that Ab42 oligomers can directly induce FXII autoactivation (Fig. 3A) . Physiologically, contact system activation takes place in the presence of prekallikrein, which is activated by FXIIa to kallikrein, which, in turn, activates additional FXII, amplifying the reaction. Ab42 dose-dependently promoted FXII activation in the presence of prekallikrein (Fig. 3B) , as seen through the reduction of FXII zymogen levels (80 kDa) and the appearance of the FXIIa heavy chain (52 kDa). Ab42 led to FXIIa-dependent FXIa generation in the absence (Fig. 3C) and presence (Fig. 3D ) of prekallikrein, indicating that FXII activated by Ab42 is capable of cleaving its substrate FXI. Previously, FXIIa-dependent FXI activation and procoagulant effects were not detected in the presence of Ab [22] . The main difference between our experiments is that the previous study used 'amorphous aggregates' of Ab42 with the Dutch mutation (E22Q) instead of the WT oligomeric Ab42 used here.
This discrepancy prompted us to analyze the ability of shown by the reduction in FXII zymogen levels at 80 kDa and the appearance of the activated FXII (FXIIa) heavy chain at 52 kDa. Dextran sulfate 500 kDa (DS500) and kaolin were used as positive controls. (C) Ab42 (3 lM) triggered FXII-dependent activated FXI (FXIa) generation in a chromogenic substrate assay. The signal was not attributable to non-specific cleavage of chromogenic substrate by FXIIa, or by autoactivation of FXI, as seen in controls where FXII or FXI was omitted. (D) FXI activation can be seen through the appearance of the 50-kDa FXIa heavy chain band following incubation of FXII, FXI, PPK, and high molecular weight kininogen (HK) with Ab42 or kaolin. Levels of FXIa heavy chain were increased in Ab42-treated (P < 0.05) and kaolin-treated (P < 0.01) samples as compared with vehicle. All lanes presented are from the same blot. (E) Ab42 oligomers were more potent in promoting FXII-dependent FXI activation than freshly dissolved Ab42. Ab42 fibrils had no effect. All Ab42 concentrations were 3 lM. (F) Ab42 oligomers were more potent than Ab40 oligomers in promoting FXII-dependent FXI activation. (G) Ab42 oligomers (transmission electron microscopy [TEM] image, top inset) promoted FXII-dependent FXI activation much more strongly than Ab42 Dutch oligomers (TEM image, bottom inset). Chromogenic substrate assays were performed in triplicate. Representative immunoblots are from three experiments. *P ≤ 0.05; **P ≤ 0.01.
Ab42 in different states of aggregation, and of other Ab variants, to trigger FXII-dependent FXI activation. We found that Ab42 oligomers had a much greater ability to trigger FXII-dependent FXI activation than freshly dissolved Ab42 (Fig. 3E ) or Ab40 oligomers (Fig. 3F) , while Ab42 fibrils produced no FXI activity at all (Fig. 3E) . Furthermore, even the most active (oligomeric) form of Ab42 Dutch was substantially less potent than oligomeric Ab42 in stimulating FXII-dependent FXI activation (Fig. 3G) , indicating that the discrepancy between our results is attributable to the use of Ab42 Dutch and the different state of Ab aggregation in the previous study.
Ab42 oligomers trigger FXII-dependent FXI activation in plasma
We next examined FXII-mediated FXI activation by Ab42 in human plasma. Biotinylated Ab42 (TEM of oligomeric preparation in Fig. S4 ), but not biotinylated amylin, was able to bind FXII in plasma, as shown by pulldown assay (Fig. 4A) , demonstrating that the Ab42-FXII interaction is specific and occurs in the presence of plasma proteins. This interaction leads to FXII activation, since plasma incubated with Ab42 had decreased FXII zymogen levels and increased FXIIa heavy chain levels compared with plasma incubated with vehicle (Fig. 4B) . Activation of FXI in plasma can be sensitively measured by quantifying FXIa-inhibitor complex levels, since FXIa generated in plasma is rapidly bound by inhibitors [48] . Incubation of plasma with Ab42 but not with Ab42 Dutch oligomers resulted in increased levels of FXIa-C1inh complex ( Fig. 4C; P < 0.001) . The activation of FXI by Ab42 was FXII-dependent, since Ab42 did not promote FXIa-C1inh complex formation in FXII-deficient plasma. The levels of FXIa in complex with a 1 AT, another FXIa inhibitor, were also increased in normal plasma following activation with Ab42 ( Fig. 4D ; P < 0.0001).
Levels of FXI zymogen and C1inh are decreased and levels of fibrin are increased in AD patient plasma
We next investigated whether the FXII-driven intrinsic coagulation pathway is activated in AD patient plasma. Two sets of AD patient and ND control plasmas were obtained from two plasma banks. Group 1 consisted of 10 AD and 10 ND samples matched with respect to age, gender, and apolipoprotein E genotype (Table S1) , and group 2 consisted of 10 AD and 10 ND samples matched with respect to age (Table S2 ). Plasma was analyzed by western blotting, with results normalized to a transferrin loading control, the levels of which are unchanged in AD patients [49] . Increased activation of FXI in plasma can be detected as decreased plasma FXI zymogen levels, which are often observed in disease states accompanied by FXI activation [48, 50, 51] , with decreased plasma FXI zymogen levels possibly reflecting continuous consumption of FXI due to its activation and clearance. AD plasma had decreased levels of FXI zymogen as compared with ND plasma in both group 1 (0. If AD plasma FXI levels were decreased because of its activation and clearance, levels of its main inhibitor C1inh [48] would also be expected to decrease. Indeed, C1inh levels were decreased in AD versus ND plasma in both group 1 (0. Fig. 5D,F) , suggesting its consumption. Decreased levels of FXI and C1inh in AD versus ND control plasma were accompanied by increased levels of FXIIa (FXIIa levels were derived from previous results [25] , and are designated by asterisks in Fig. 5B,C) . This relationship suggests that depletion of FXI and C1inh in AD patient plasma is attributable to FXII activation.
Activation of the intrinsic pathway of coagulation would be expected to result in increased thrombin generation and fibrin formation. Indeed, AD patients from group 2 had elevated plasma fibrin (0. (Fig. 5G-I) . Levels of fibrin and Ddimer were inversely correlated with FXI levels (r = À 0.46, P = 0.04 for fibrin; r = À 0.57, P = 0.008 for D-dimer; Fig. 5J ), suggesting that activation and subsequent clearance of FXI results in thrombin generation and fibrin formation. In group 1, there was a non-significant trend towards increased fibrin levels in AD plasma (data not shown), which could be attributable to differences in blood draw and anticoagulation methods between the groups (see Materials and methods). Another possible explanation is the more advanced disease stage of patients in group 1 than of patients in group 2 as determined by the CDR score measuring cognitive function, where 0 = no dementia and 3 = severe dementia [45] (2.0 AE 1.1 for group 1 versus 1.0 AE 0.6 for group 2, P = 0.028; Tables S1 and S2). Since group 1 patients are likely to have been exposed to FXI activation for a longer time due to more advanced disease the fibrin formed may have been progressively deposited, thereby depleting soluble fibrin from plasma.
Discussion
Our results identify Ab as a prothrombotic factor that can trigger thrombin generation via FXII-dependent activation of FXI. Ab42-mediated, FXII-dependent FXI activation was previously not found [22] , likely because amorphous aggregates of Ab42 with the Dutch mutation (E22Q) were used. While that study found no FXI activation with Ab42 Dutch amorphous aggregates, our results with Ab42 Dutch oligomers showed low levels of FXII-dependent FXI activation, highlighting the importance of the assembly state of Ab42 Dutch in FXI activation. We also showed that WT oligomeric Ab42 was a more potent FXI activator than monomeric and fibrillar preparations, further supporting the importance of Ab aggregation state. Finally, WT Ab42 oligomers were much more potent in FXI activation than Ab42 Dutch oligomers, possibly because of differences in peptide charge (À 2.7 for Ab42 versus À 1.7 for Ab42 Dutch at pH 7). A more negative charge and/or the presence of glutamic acid at position 22 of Ab42 therefore appears to be crucial for its activation of FXII and FXI, and it is possible that this region is more optimally exposed in oligomers.
Ab's role as a prothrombotic factor is interesting in the context of the anticoagulant properties of its parent molecule amyloid precursor protein (APP). Some isoforms of APP contain a Kunitz protease inhibitor domain that Non-reducing western blot analysis of FXI, C1inh and transferrin loading control in plasma of 10 AD patients and 10 non-demented (ND) controls from group 1. Lanes loaded with FXI purified protein (FXI) and FXI-deficient human plasma show that the band just above the FXI band is non-specific. (B) FXI levels normalized to transferrin were lower in AD plasma than in ND plasma (P = 0.008). Levels of FXIIa normalized to transferrin in these samples were determined previously [25] , and mean values for each group are designated by asterisks. (C) C1inh levels were lower in AD plasma than in ND plasma (P = 0.0008). Levels of FXIIa normalized to transferrin in these samples were determined previously [25] , and mean values for each group are designated by asterisks. (D) Levels of FXI, C1inh and transferrin were analyzed in 10 AD and 10 ND plasmas from group 2. (E) FXI levels were lower in AD plasma than in ND plasma (P = 0.0003). (F) C1inh levels were lower in AD plasma than in ND plasma (P = 0.01). (G) Levels of fibrin monomer were analyzed under reducing conditions in 10 AD and 10 ND plasma samples from group 2 with antibody 59D8 specific for fibrin b-chain [46] . (H) D-dimer levels were analyzed under non-reducing conditions in 10 AD and 10 ND plasma samples from group 2. (I) Fibrin (P = 0.009) and D-dimer (P = 0.018) levels were increased in group 2 AD plasma compared to control. (J) Fibrin (r = À 0.49; P = 0.03) and D-dimer (r = À 0.57, P = 0.008) levels were negatively correlated with FXI levels in samples from group 2. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001. inhibits several coagulation factors [52] [53] [54] . As protease activation is often accompanied by activation of corresponding inhibitory pathways, the release of soluble APP (sAPP) during Ab production may attenuate the prothrombotic pathways initiated by Ab. Dysregulation of the balance between Ab and sAPP may lead to thrombosis or hemorrhage, depending on their abundance and/or localization. For example, an excess of Ab over sAPP may occur in the cerebral circulation of AD patients because of transport of Ab from the brain parenchyma [55] without corresponding transport of sAPP. Our hypothesis that circulating Ab triggers a prothrombotic state in AD is supported by increased levels of Ab42 oligomers (in the nanomolar range, similar to the levels used in our thrombin generation studies) in AD patient plasma [56] . Interestingly, higher Ab42 levels are found in sporadic and familial AD at early stages of disease, prior to and just at the onset of symptoms [33] [34] [35] 57] . It is thus tempting to speculate that the Ab/FXIIdependent prothrombotic state suggested by our results together with Ab/FXII-mediated proinflammatory events [25] may trigger AD-related vascular pathology when combined with age-mediated or vascular risk factormediated changes.
In AD and pre-AD states, circulating Ab may induce chronic, low-level FXII-dependent FXI activation. This is supported by increased FXIIa levels [25] and decreased levels of FXI zymogen and its inhibitor C1inh in AD patient plasma, which could reflect the clearance of the FXIa-C1inh complex following FXII-dependent FXI activation [58] . C1inh depletion in AD plasma may also stem from inhibition of FXIIa and kallikrein, which are activated in the intrinsic coagulation pathway. Our results are in agreement with the decreased levels of C1inh previously found in plasma from individuals with mild cognitive impairment and AD [59, 60] . Although our data suggest that FXI consumption is attributable to its activation by FXII, it is possible that some FXI consumption results from feedback activation by thrombin following extrinsic pathway activation.
Chronic FXI activation could mediate the production of low 'idling' levels of thrombin, which may contribute to the chronic formation of fibrin; this is supported by increased fibrin monomer and D-dimer levels in the plasma of AD patients from group 2. Elevated plasma fibrin monomer levels are observed in procoagulant states such as coronary artery disease [61] , venous thrombosis [62] , and myocardial infarction [63] , among others. In AD, chronic thrombin generation could lead to the formation of persistent clots with decreased susceptibility to fibrinolysis, due to Ab's ability to induce the formation of a fibrinolysis-resistant fibrin network [64] . Indeed, formation of persistent clots is observed in an AD mouse model [7] , and increased deposition of fibrin occurs in the brains of AD patients and mouse models [65] .
Increased thrombosis in AD would have significant consequences for vascular and neuronal health. Thrombus formation in arterioles and venules decreases blood flow in surrounding capillaries [66, 67] , limiting oxygen and nutrient supply to neurons. Furthermore, thrombin mediates BBB breakdown [68] , and the resulting plasma protein access to the vessel wall and brain parenchyma could contribute to vascular and neuronal damage. Targeting FXII, the intrinsic coagulation pathway, thrombin activity and thrombus formation in AD could therefore provide novel therapeutic opportunities. Addendum D. Zamolodchikov designed the study, performed experiments, analyzed data, and wrote the manuscript. T. Renn e and S. Strickland designed the study, analyzed data, and participated in manuscript preparation.
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